

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/790,943
Date Submitted: March 23, 2009 (use as many sheets as necessary)				Filing Date	9/3/2002
				First Named Inventor	William Robert Wilson
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	1	of	2	Attorney Docket Number	093397-0501

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

<b>UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
	F1	DE 19721211A1	11-26-1998	Lindner	
	F2	DE 2015265 A1	10-08-1970	Yoshitomi Pharmaceutical Industries, Ltd.	

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	D49	Arends, et al., "A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma", <i>British Journal of Cancer</i> , 92(3):445-448 (2005).			
	D50	Calabresi, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, Section X, Chemotherapy of Neoplastic Diseases, 9th Edition:1225-1229 (1995).			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SVCA\_284790.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Date Submitted: March 23, 2009 (use as many sheets as necessary)			
Sheet	2	of	2
<i>Complete If Known</i>			
Application Number		10/790,943	
Filing Date		9/3/2002	
First Named Inventor		William Robert Wilson	
Art Unit		1614	
Examiner Name		James D. Anderson	
		Attorney Docket Number	
		093397-0501	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
	D51	Corrie, et al., "Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients", <i>British Journal of Cancer</i> , 87(7):716-719 (2002).
	D52	Gridelli, et al., "Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial", <i>Journal of the National Cancer Institute</i> , 95(5):362-372 (2003).
	D53	Hill, et al., "Anti-Vascular Approaches To Solid Tumour Therapy: Evaluation of Vinblastine and Flavone Acetic Acid", <i>Int. J. Cancer</i> , 63:119-123 (1995).
	D54	Jordan, et al., "Comparison of the Effects of Vinblastine, Vincristine, Vindesine, and Vinorelbine on Microtubule Dynamics and Cell Proliferation in Vitro", <i>Cancer Research</i> , 45:2741-2747 (1985).
	D55	Larsen, et al., "From DNA damage to G2 arrest : the many roles of topoisomerase II", <i>Progress in Cell Cycle Research</i> , 5:295-300 (2003).
	D56	Onn, et al., "Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib", <i>British Journal of Cancer</i> , 91(Suppl. 2):S11-S17 (2004).
	D57	PTCL Safety Glossary: Structure-Activity Relationship, ptcl.chem.ox.ac.uk/MSDS/glossary/structure_activity_relationship.html, June 27, 2003, 1 page
	D58	Strauss, et al., "A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma", <i>British Journal of Cancer</i> , 89(10):1901-1905 (2003).
	D59	Yokoi, et al., "Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine", <i>Clinical Cancer Research</i> , 10:2299-2306 (2004).

Examiner Signature	/James Anderson/	Date Considered	04/17/2009
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SVCA\_284790.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/